Trial Profile

Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARION

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Sep 2025 According to an EMD Serono media release, data fromthis study presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona.
01 Jul 2022 Patients characteristics and design published in the Current Medical Research and Opinion
25 Aug 2021 Results assessing data quality over time in MS registries participating in CLARION through the use of pre-defined DQIspresented at the 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com